Nutriflex Omega Peri 32/64

Valine, the active ingredient in Nutriflex Omega Peri 32/64, the active ingredient in Nutriflex Omega Peri 32/64, is a branched‑chain amino acid presented as a nutritional supplement for oral use. It supports metabolic and protein synthesis pathways in patients requiring enhanced nutritional support, particularly in peri‑operative and critical care settings.

GNH USA supplies Nutriflex Omega Peri 32/64 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Nutriflex Omega Peri 32/64 provides essential amino acids for patients with increased metabolic demand, particularly within the peri‑operative and critical‑care spectrum. - Peri‑operative nutrition: Helps maintain nitrogen balance and supports wound healing after surgery. - Critical‑care support: Contributes to protein synthesis and muscle preservation in intensive care patients. - Malnutrition management: Assists in correcting amino‑acid deficiencies in patients with prolonged catabolism.

Nutriflex Omega Peri 32/64 may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild gastrointestinal discomfort reported by some patients. - Vomiting: occasional emesis, often related to rapid infusion. - Diarrhoea: loose stools occurring during early administration. - Abdominal discomfort: cramping or bloating sensations. - Metallic taste: transient alteration in taste perception. - Injection site irritation: redness or mild pain if administered intravenously.

Serious or Rare Side Effects: - Hyperammonemia: elevated blood ammonia levels in patients with severe liver dysfunction. - Allergic reaction: rash, urticaria or anaphylaxis in hypersensitive individuals. - Metabolic acidosis: rare disturbance of acid‑base balance. - Electrolyte imbalance: abnormal potassium or calcium levels. - Sepsis‑like syndrome: extremely rare systemic inflammatory response. - Renal impairment: worsening kidney function in predisposed patients.

When considering Nutriflex Omega Peri 32/64, clinicians should evaluate patient‑specific factors and monitor relevant clinical parameters. - Renal function: assess baseline creatinine and adjust if impairment is present. - Hepatic function: monitor liver enzymes and ammonia levels in patients with liver disease. - Electrolytes: check serum potassium, calcium and magnesium before and during therapy. - Metabolic status: observe for signs of acidosis or hyperglycaemia. - Infusion rate: administer according to institutional protocols to minimise gastrointestinal upset. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Nutriflex Omega Peri 32/64 contains amino acids that can influence the pharmacokinetics of certain concomitant medicines.

Major Interactions (Avoid): - High‑dose leucine supplements: may exacerbate metabolic imbalances. - Nitrogen‑bearing diuretics (e.g., acetazolamide): increase risk of electrolyte disturbances. - Anticonvulsants (e.g., valproate): potential for altered ammonia metabolism.\n Moderate Interactions (Monitor Closely): - Insulin therapy: amino acids can stimulate insulin release, requiring glucose monitoring. - Thyroid hormone replacement: may affect protein turnover rates. - Warfarin: protein intake changes can modify INR stability. - Corticosteroids: synergistic catabolic effects may necessitate dose adjustment. - Oral rehydration solutions: high sodium content may compound electrolyte shifts.